The Trust Layer for Market Analysts

Novo Nordisk (NVO) faces significant headwinds with its Alzheimer's treatment trials failing to meet expectations, causing the stock to trade near its 52-week low. Despite a recent partial recovery, the stock is down 6% today. The company's intrinsic value is calculated at $87.74 per share, suggesting it is currently undervalued. However, investors are cautioned not to expect a quick turnaround, as a positive catalyst from its oral weight-loss pill, approved in the US, is anticipated early next year. This could potentially shift the stock's direction and hit an inflection point, but its actual impact remains to be seen.